Related references
Note: Only part of the references are listed.Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
Mary L. Disis
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Selenium and the Selenoprotein Thioredoxin Reductase in the Prevention, Treatment and Diagnostics of Cancer
Markus Selenius et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Thioredoxin and thioredoxin reductase: Current research with special reference to human disease
Arne Holmgren et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Pre-operative intracellular glutathione levels of peripheral monocytes as a biomarker to predict survival of colorectal cancer patients
Kazuko Uno et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Th17 cells: positive or negative role in tumor?
Yuqiang Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
Lilja Thoenes et al.
JOURNAL OF PROTEOMICS (2010)
The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells
Selena Kuljaca et al.
CARCINOGENESIS (2009)
Identification of human thioredoxin as a novel IFN-gamma-induced factor: Mechanism of induction and its role in cytokine production
Seol-Hee Kim et al.
BMC IMMUNOLOGY (2008)
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update
S. H. Beachy et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants
Jenny Ceccarelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
A Novel Role of CD30L/CD30 Signaling by T-T Cell Interaction in Th1 Response against Mycobacterial Infection
Ce Tang et al.
JOURNAL OF IMMUNOLOGY (2008)
Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness
Luksana Chaiswing et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1
Ulla Schwertassek et al.
EMBO JOURNAL (2007)
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer
Hans J. J. van der Vliet et al.
CLINICAL CANCER RESEARCH (2007)
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease
Robert Zeiser et al.
BLOOD (2007)
A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage
Lawrence Steinman
NATURE MEDICINE (2007)
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro
Dennis A. Eichenauer et al.
CANCER RESEARCH (2007)
Thioredoxin and related molecules - From biology to health and disease
Christopher Horst Lillig et al.
ANTIOXIDANTS & REDOX SIGNALING (2007)
Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-α expression but decrease functional transcriptional activity, DNA binding, and degradation
Dylan T. Jones et al.
CLINICAL CANCER RESEARCH (2006)
Thioredoxin reductase as a novel molecular target for cancer therapy
Phuongmai Nguyen et al.
CANCER LETTERS (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer
SJ Kim et al.
CLINICAL CANCER RESEARCH (2005)
Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma
C Nishioka et al.
CANCER SCIENCE (2005)
CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance - The role of IFN beta-1a in the treatment of multiple sclerosis
P Pellegrini et al.
NEUROIMMUNOMODULATION (2005)
The mammalian testis-specific thioredoxin system
A Miranda-Vizuete et al.
ANTIOXIDANTS & REDOX SIGNALING (2004)
Effective immunotherapy against cancer - A question of overcoming immune suppression and immune escape?
KJ Malmberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response
P Pellegrini et al.
TRANSPLANT IMMUNOLOGY (2003)
Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus
M Saraiva et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis
H Muta et al.
JOURNAL OF IMMUNOLOGY (2000)
The role of the redox protein thioredoxin in cell growth and cancer
G Powis et al.
FREE RADICAL BIOLOGY AND MEDICINE (2000)
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival
TM Grogan et al.
HUMAN PATHOLOGY (2000)
Share Paper
